Oncoceutics announced today that Michael Chiarella, an industry veteran with more than 20 years’ experience at a number of large and small biotech companies, is joining the company as Vice President, Clinical Operations
Philadelphia, PA (May 13, 2019) –Oncoceutics announced today that Michael Chiarella, an industry veteran with more than 20 years’ experience at a number of large and small biotech companies, is joining the company as Vice President, Clinical Operations. Mr. Chiarella will be responsible for building out Oncoceutics’ clinical operations in connection with the company’s preparation for an eventual filing of a New Drug Application (NDA) for Oncoceutics’ lead compound, ONC201.
ONC201 is currently in Phase II clinical trials for a number of oncology indications, including adult recurrent H3 K27M-mutant high-grade glioma, an indication for which the company has received Fast Track designation from the U.S. Food and Drug Administration (FDA). As the company prepares to transition this Phase II trial into a pivotal program and convert from an early-stage drug discovery and development company into a fully-integrated pharmaceutical company, it will continue to build its clinical operations capabilities.
“We are delighted to have an individual with Michael Chiarella’s extensive know-how joining Oncoceutics,” said Lee Schalop, MD, Chief Operating Officer of Oncoceutics. “Michael’s experience in building a completely integrated clinical operations team at companies like Celator Pharmaceuticals and Aton Pharmaceuticals is a perfect fit for Oncoceutics as we grow our clinical operations.”
“I am excited to be joining the dedicated and experienced group of individuals at Oncoceutics,” said Mr. Chiarella. “Novel therapies are desperately needed for the treatment of brain cancer, and I look forward to using my experience in the development process to help move ONC201 rapidly forward toward regulatory approval.”
About Oncoceutics
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds, called “imipridones,” that selectively target G protein-coupled receptors for oncology. The first lead compound to emerge from this program is ONC201, an orally active small molecule DRD2 antagonist. The company is supported by grants from NCI, FDA, The Musella Foundation, and a series of private and public partnerships. Visit Oncoceutics for more information.
